Systemic therapy of advanced urothelial cancer

Current Treatment Options in Oncology

Volumn 10, Issue 3-4, 2009, Pages 256-266

  Vaishampayan, Ulka ^a  

^a 4HWCRC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAROTAXEL; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN P53; TRASTUZUMAB; VANDETANIB; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ALOPECIA; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HUMAN; METASTASIS; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SEPSIS; SYSTEMIC THERAPY; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; UROTHELIUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PATIENT SELECTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 70350295877     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-009-0101-9     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. doi: 10.3322/CA.2007.0010.
2. Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003, 349:859-66. doi: 10.1056/NEJMoa022148.
3. Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA Jr: Complications of radical cystectomy for nonmuscle invasive disease: Comparison with muscle invasive disease. J Urol. 2003, 169:101-104.
4. Herr HW, Schwalb DM, Zhang ZF, et al.: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995, 13:1404-1408.
5. Steinberg, G; Bahnson, R; Brosman, S, et al.: Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000, 163:761-767.
6. Bianco FJ Jr, Justa D, Grignon DJ, et al.: Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol. 2004, 4:290-294.
7. Margulis V, Shariat SF, Matin SF, et al.: Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009 Jan 20 [Epub ahead of print]
8. Patel B, Forman J, Fontana J, et al.: A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys. 2005, 62:1332-1338.
9. Walko CM, Lindley C. Capecitabine: A review. Clin Ther. 2005, 27:23-44.
10. Fabio C. and Sternberg C.N.: Neoadjuvant and adjuvant therapy in muscle invasive bladder cancer. Eur Urol 2009, 55:348-358.
11. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003, 361:1927-1934.
12. Millikan, C. Dinney and D. Swanson et al.: Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005-4013.
13. Lara PN, Goldman B, DeVere WR, et al.: A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG). J Clin Oncol 2008, 26 (abstract # 5022)
14. Smith DC, Mackler NJ, Dunn RL, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008, 180:2384-2388.
15. Sternberg CN, Yagoda A, Scher HI, et al.: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988, 139:461-469.
16. Saxman SB, Propert KJ, Einhorn LH, et al.: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997, 15:2564-2569.
17. H. von derMaase, S.W. Hansen, J.T. Roberts, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol 2000, 18:3068-3077.
18. Redman BG, Smith DC, Flaherty L, et al.: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998, 16:1844-1888.
19. M. Hussain, U. Vaishampayan, W. Du, et al.: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer, J Clin Oncol 2001, 19:2527-2533.
20. J.D. Hainsworth, A.A. Meluch, S. Litchy, et al.: Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium, Cancer 2005, 103:2298-2303.
21. Bellmunt J, von der Maase H, Mead GM, et al.: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. ASCO 2007 (abstract # LBA5030)
22. Bajorin DF, Dodd PM, Mazumdar M, et al.: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999, 17:3173-3181.
23. De Wit R.: European Organization for Research and Treatment. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer. 2003, 97(8 Suppl):2120-2126.
24. Witte RS, Elson P, Bono B, et al.: Eastern Cooperative Oncology Group trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589-593, 1997.
25. Kim J, Millikan RE, SmithTL, et al.: Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: A phase II study. Urol Oncol 2003, 21:21-26.
26. Witte RS, Elson P, Khandakar J, et al.: An Eastern Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 1994, 73:688-691.
27. C. Sweeney, Roth BJ, Kabbinavar FF, et al.: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the bladder. J Clin Oncol 2006, 24:3451-3457.
28. Vaishampayan UN, Faulkner JR, Small EJ, et al.: Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: A Southwest Oncology Group study. Cancer. 2005 Oct 15;104(8):1627-32.
29. Uhm JE, Lim HY, Kim WS, et al.: Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia. 2007, 1:18-22.
30. Carles J, Esteban E, Climent M, et al.: Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007, 8:1359-1362.
31. Logothetis CJ, Dexeus FH, Sella A, et al.: Escalated therapy for refractory urothelial tumors; methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony- stimulating factor. J Natl Cancer Inst 1990, 18:667-672.
32. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006, 94:1395-1401.
33. Bellmunt Molins J, von der Maase H, Theodore C, et al.: Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol 2008, 26 (abstr 5028)
34. Jimenez RE, Hussain M, Bianco FJ Jr, et al.:HEr-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001, 8:2440-2447.
35. M.H. Hussain, G.R. MacVicar, D.P. Petrylak, et al.: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial, J Clin Oncol 2007, 25:2218-2224.
36. Bradley DA, Dunn R, Nanus D, et al.: Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design. Clin Genitourin Cancer 2007, 5:460-463.
37. Sakr W, Marur S, Che M, et al.: Expression of EGFR, HER-2 and p53 predictive of prognosis in muscle-invasive bladder cancer. ASCO 2007 (abstract # 15637)
38. Bellmunt J, Hussain M, Dinney CP.: Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003, 46 Suppl:S85-104.
39. Philips GK, Halabi S, Sanford BL, et al.: A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009 Jan 23 [Epub ahead of print]
40. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR.: Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens - evidence of schedule-dependent synergy. Urology. 2007,69:390-394.